AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. DMART:IN
8. HUM
9. KTOS
10. NVDA

Go back to AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales

Mizuho Securities Reiterates Buy Rating on Evolus (EOLS) Following 3Q Beat

November 5, 2019 7:22 AM EST

Mizuho Securities analyst Difei Yang reiterated a Buy rating and $30.00 price target on Evolus (NASDAQ: EOLS) following the company's 3Q earnings report. Both revenue and EPS came in above consensus estimates, driven by strong sales from Jeuveau in the... More

Evolus (EOLS) Tops Q3 EPS by 15c, Revenues Beat

November 4, 2019 7:09 AM EST

Evolus (NASDAQ: EOLS) reported Q3 EPS of ($0.98), $0.15 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $4.05 million.

This was an exceptional quarter for the company on many fronts, in the U.S. and internationally,... More